Peripheral neuropathy Nervous System Diseases Other polyneuropathies
Conditions
Interventions
Topical application of Neuragen® versus placebo. The medicine was sprayed onto the subjects feet at the sole and on top of the feet. One time application with an 8-hour follow-up.
Sponsors
Origin BioMed, Inc. (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female, over 21 years 2. Diagnosed neuropathic pain for more three months 3. Pain level between 3 - 8 on a 0 - 10 visual pain scale 4. Does not have mental and communication impairments
Exclusion criteria
Exclusion criteria: 1. Pregnant 2. Have other types of pain 3. Skin condition 4. Central nerve impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Foot sole pain on 11-point numerical pain scale. 0 - 10 visual analog scale was use to document pain level at 30 minutes before and after the administration of the medication, with 8-hour follow up every hour on the hour. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of pain reduction. 0 - 10 visual analogue scale was use to document pain level at 30 minutes before and after the administration of the medication, with 8-hour follow up every hour on the hour. | — |
Countries
United States of America
Outcome results
None listed